Abstract: Gold nanoparticles are conjugated to phosphatidylserine-specific ligands for targeting and binding to surface-exposed phosphatidylserine on tumor cells and tumor vasculature. The ligand may be an annexin (e.g., annexin V). Tumor contrast is significantly increased using the targeted gold nanoparticles. Breast cancer tumors as small as 4 mm, for example, were detectable via computed tomography (CT) within 4 hours after injection of the conjugates, demonstrating usefulness of the conjugates as imaging agents. The targeted gold nanoparticle conjugate may further have a drug conjugated thereto that can be used therapeutically, for example, for cancer treatment. The gold nanoparticle conjugates can also be used for photothermal therapy and can be used in concert with an X-ray radiation treatment for cancer treatment.

Abstract: This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.

Abstract: The present invention provides a method of PEGylating a human truncated cystathionine ?-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.

Abstract: Provided are compositions and methods for inhibiting extracellular matrix metalloproteinase-2 (MMP-2) activity. Inhibition of extracellular MMP-2 activity can be useful for restricting extracellular matrix remodeling, tumor cell migration, cell invasion, and/or metastasis. The compositions comprise mutants of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2), where the tyrosine at position 62, 90 and/or 165 has been substituted with a non-phosphorylatable amino acid or with a phosphomimetic of phosphorylated tyrosine, and/or anti-Src antibodies. The method comprises delivering to an extracellular region of a tissue, a composition comprising a TIMP-2 mutant and/or an anti-Src antibody.

Abstract: Disclosed are components, systems, and methods for glycoprotein or recombinant glycoprotein protein synthesis in vitro and in vivo. In particular, the present invention relates to components, systems, and methods for identifying amino acid glycosylation tag motifs for N-glycosyltransferases and the use of the identified amino acid glycosylation tag motifs in methods for preparing glycoproteins and recombinant glycoproteins in vitro and in vivo.

Abstract: Provided is a multivalent protein that targets interaction of SARS-CoV-2 spike receptor binding domain (RBD) with the human angiotensin-converting enzyme 2 (ACE2) receptor protein. The multivalent proteins may also be used to treat subjects having cancer and/or a disease and/or viral infection. Also presented is a multiplex lateral flow test strips for simultaneous detection of the virus and viral antibodies.

Abstract: A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.

Abstract: Provided herein are methods, compositions, and devices for occluding cavities or passageways in a patient, in particular cavities or passageways in the cardiovascular system of a patient, such as the LAA of a patient's heart. The methods, compositions, and devices can be used to percutaneously occlude the LAA, decreasing the risk of thromboembolic events associated with AF.

Abstract: A method for purifying a specific trityl group-containing monodispersed polyethylene glycol from a mixture containing the trityl group-containing monodispersed polyethylene glycol and a specific ditritylated impurity. The method includes performing steps (A), (B) and (C). Step (A): a step of esterifying the hydroxyl group of the trityl group-containing monodispersed polyethylene glycol by a specific method; Step (B): a step of extracting the esterified compound by a specific method; and Step (C): a step of hydrolyzing the esterified compound to obtain the trityl group-containing monodispersed polyethylene glycol.

Abstract: Provided herein are compositions, systems, and methods for minimally-invasive assessment of toxicity-induced tissue injury. In particular, external (e.g., whole-body) scanning is employed to detect toxicity-induced injuries, such as those caused by chemotherapeutics.

Abstract: Certain aspects of the present invention relate to modified hemoglobin proteins comprising at least one modification (e.g., at the thiol group of an exogenous amino acid residue) for homogenous conjugation of one or more polymeric moieties e.g. polyethylene glycol or derivatives thereof. Also included herein are methods of using such modified proteins and compositions comprising such proteins, e.g. in therapy.

Abstract: Disclosed are a multifunctionalized polyethylene glycol derivative and a preparation method therefor. The derivative has an H-shaped structure as represented by formula (1) and comprises one linear core LPEG and four PEG branch chains, where n1, n2, n3, and n4 respectively are the degrees of polymerization of the branch chains, U1 and U2 are trivalent branching groups connecting the core LPEG to two of the PEG branch chains, F1 and F2 contain a functional group or a protected form R01 thereof and may or may not contain a branched group G, correspondingly, the number of R01 is one or more, F1 and F2 are either identical or different, any one linking group in the molecule or any linking group formed with an adjacent heteroatom group can either remain stable or be degraded, and any one PEG segment in the molecule is discretely polydispersed or monodispersed.

Abstract: This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.

Abstract: Disclosed herein are methods and compositions for making vault particles in yeast hosts and yeast vaults produced therefrom.

Abstract: The present invention relates to a prefunctionalized metallic nanoparticle (10) as a standardized basic building block of biofunctionalized nanoparticles (40), having a thiol-reactive metallic nanoparticle (12) that is prefunctionalized by a bifunctional molecule (20) that consists of an anchor component (22) and a short further-functionalization stub (24). Here, it is provided that the anchor component (22) comprises one or more dithiophosphate groups, and the short further-functionalization stub (24) is adapted for the attachment of a desired biofunctionalization (30) and is selected from the group consisting of i) an unmodified standardized oligonucleotide strand (26) having 2 to 18 bases for further-functionalization with biomolecules (30) having a terminal complementary strand (36) of the standardized oligonucleotide strand (26), and ii) a 2- to 18-base-long oligonucleotide strand (50; 60) that is modified with a terminal reactive group (52; 62) for biomolecules.

Abstract: The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.

Abstract: The present invention, relates to composition of matter comprising sequence variants of Stable Protein 1 (SP1) and carbon nanotubes or carbon black, and optionally comprising latex. This invention also relates to surfaces (e.g. metal wires, cords, and polymeric and non polymeric fibers, yarns, films or fabrics, wood and nano, micro and macro particles) comprising this composition of matter, to methods for producing them, and to uses thereof in the preparation and formation of improved composite materials, including rubber, and rubber compound composites.

Abstract: Provided is a cyclic peptide, which is represented by Formula (I) or Formula (I?) and has excellent antibody binding properties and improved chemical resistance, an affinity chromatography support, a labeled antibody, an antibody drug conjugate, and a pharmaceutical preparation. RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC??(I) In Formula (I), Xa and Xb each independently represent an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and are bonded to each other through a disulfide bond, or, one of Xa and Xb represents an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and the other represents an amino acid residue derived from an amino acid having a haloacetyl group on a side chain, and Xa and Xb are bonded to each other through a thioether bond.

Abstract: Provided is a cyclic peptide, which is represented by Formula (I) or Formula (I?) and has excellent antibody binding properties and improved chemical resistance, an affinity chromatography support, a labeled antibody, an antibody drug conjugate, and a pharmaceutical preparation. RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC??(I) In Formula (I), Xa and Xb each independently represent an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and are bonded to each other through a disulfide bond, or, one of Xa and Xb represents an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and the other represents an amino acid residue derived from an amino acid having a haloacetyl group on a side chain, and Xa and Xb are bonded to each other through a thioether bond.

Abstract: The present specification relates to a carrier-nanoparticle complex, a catalyst including the same, an electrochemical battery or a fuel cell including the catalyst, and a method for preparing the same.

Abstract: Compounds according to Formula I are provided: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Formula I are also provided, as well as methods of treating cellular proliferative disorders, such as cancer, using compounds of Formula I.

Abstract: There is provided a method of manufacturing a toner including a toner particle containing a binder resin, the method including: process 1: preparing a mixed solution including the following components i) to iii) in an aqueous medium: i) a particular silicon compound, ii) a fine particle having a number average particle diameter of 3 nm or more and 500 nm or less, and iii) a toner base particle containing the binder resin; and process 2: adjusting a pH of the mixed solution to 7.0 or more and 12.0 or less to condense the silicon compound, wherein the fine particle has an absolute value of zeta potential of 10.0 mV or more at the pH of the mixed solution of process 1.

Abstract: Described herein are methods, compositions and kits utilizing heterogeneous metal catalysts for the preparation of cycloaddition compounds, such as triazoles and biomolecules.

Abstract: The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention.

Abstract: Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a ?-elimination mechanism.

Abstract: It is intended to provide a detection method and a determination method for detection target capable of detecting and determining a detection target promptly and simply with high accuracy at low cost. The detection method includes the steps of: mixing a first conjugate 10 in which a first substance containing a stimulus-responsive polymer 11 and a particulate magnetic substance 19 is conjugated to a first antibody 13 against a detection target 50 with a sample; applying a magnetic force after placing the resulting mixture in a condition capable of aggregating the stimulus-responsive polymer 11; measuring a generated magnetic field; and detecting the detection target 50 based on the degree of increase in the magnetic field after applying the magnetic force.

Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).

Abstract: The present invention relates to a method of producing a dispersion comprising a) mixing an aqueous dispersion of silanized colloidal silica particles with at least one organic compound containing at least two hydroxyl groups to provide an aqueous dispersion of silanized colloidal silica particles and said at least one organic compound, wherein the mixing is performed in the substantial absence of any monofunctional alcohol b) withdrawing water from the formed aqueous dispersion until the remainder of water in the dispersion is below about 10 wt %. The invention also relates to a dispersion obtainable therefrom and the use of the dispersion.

Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject.

Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.

Abstract: There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. A method for pre-treating a glycated hemoglobin-containing sample for an immunological assay of glycated hemoglobin, the method includes treating a glycated hemoglobin-containing sample with a pre-treatment solution containing (A) guanidine or a salt thereof and (B) a nonionic surfactant and/or a nitrite.

Abstract: A peptide inhibiting a matrix metalloproteinase activity, thereby improving the condition of skin and a composition containing the peptide is described, where the peptide comprises an amino acid sequence represented by the formula: Xaa1-Xaa2-Pro-Cys-Xaa3-Xaa4-Xaa5-Ser-Xaa6and has excellent bioactivities of inhibiting the activity of hyaluronic acid degrading enzymes, adipogenesis in fat cells, angiogenesis, and the like, thereby being useful for the treatment of various disease such as obesity, cancer, and inflammation.

Abstract: It is provided a method of treating a disorder, the method comprising implanting in a patient an implantable device including a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.

Abstract: It is provided a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.

Abstract: Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to control (e.g., promote or inhibit) signaling, and, therefore, the ligand dimers provided can also be used in various forms of treatment in which such signaling control is beneficial to a subject. It follows that methods for controlling signaling are provided as are various methods of treatment.

Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

Abstract: Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB 1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of ErbB1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.

Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

Abstract: This invention provides a biomolecule modifying substrate comprising biomolecules selectively fixed to given regions thereon. The biomolecule modifying substrate comprises: a substrate at least comprising a first surface and a second surface; a first linker molecule comprising a hydrocarbon chain and a functional group capable of selectively binding to the first surface at one end of the hydrocarbon chain, which is bound to the first surface via such functional group; a second linker molecule comprising a reactive group capable of binding to the hydrocarbon chain of the first linker molecule, which is bound to the first linker molecule via a bond between the reactive group and the hydrocarbon chain; and a biomolecule bound thereto via the second linker molecule.

Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.

Abstract: There is disclosed a method for producing a molecule immobilizing substrate, comprising at least the steps of: forming, on a substrate, a monomolecular film including hydroxyl groups, cyano groups, or oxiranyl groups, which are oriented toward an outmost surface of the monomolecular film; and chemically modifying the hydroxyl groups, cyano groups, or oxiranyl groups of the monomolecular film to transform them into carboxyl groups, to thereby form, on the substrate, the monomolecular film including the carboxyl groups, which are oriented toward an outmost surface of the monomolecular film. There can be provided: a method for producing a molecule immobilizing substrate which is free of occurrence of an immobilized-molecule peeling problem in the case of conducting an assay by immobilizing molecules on the substrate.

Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.

Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.

Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Abstract: The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of: 1) replacement of the 36th serine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 2) replacement of the 80th tryptophan residue of SEQ ID NO: 2 with a hydrophilic amino acid residue; 3) replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 4) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 78th threonine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 5) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid that

Abstract: A method for manufacturing cubic diamond nanocrystals (10) comprising the following successive steps: (a) providing crystalline diamond powder where the maximum particle size of the powder is equal or more than 2 ?m and equal or less than 1 mm; (b) milling said crystalline micron diamond powder using nitrogen jet milling micronization so as to manufacture a fine powder; (c) nanomilling the fine powder of step b) using a planetary tungsten carbide ball mill; (d) acid treating the nanomilled powder of step c); (e) extracting the cubic diamond nanocrystals (10) by centrifugation. Advantageously round-shaped cubic diamond nanocrystals are manufactured.

Abstract: A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions. These composites have also been found to be strong tissue adheives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound.

Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.